Patents by Inventor Bo Kreilgaard

Bo Kreilgaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic formulation for administering tolterodine with controlled release
    Patent number: 6770295
    Abstract: The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: August 3, 2004
    Assignee: Pharmacia AB
    Inventors: Bo Kreilgård, Lene Orup Jacobsen, Ulla Hoeck, Helle Kristensen, Torkel Gren, Lisbeth Nilvebrant, Anders Ringberg, Martin Wikberg, Bengt Hallén, Birgitta Olsson, Jan Strömbom
  • Novel compositions of potassium channel openers and protein kinase C inhibitors and use thereof
    Publication number: 20020137692
    Abstract: Novel compositions comprising a potassium channel opener, such as minoxidil, and a protein kinase C inhibitor, such as procyanidin B2 are presented, as are kits containing a first composition comprising a potassium channel opener and a second composition comprising a protein kinase C inhibitor. Also presented are methods for using the novel compositions for treating and preventing hair loss in a region of a patient.
    Type: Application
    Filed: January 29, 2002
    Publication date: September 26, 2002
    Applicant: Pharmacia AB
    Inventors: Jan Rundegren, Bo Kreilgaard
  • Transdermally administered dextromethorphan as antitussive agent
    Patent number: 6335030
    Abstract: The present invention is drawn to a device for the transdermal administration of dextromethorphan, (+)-3-methoxy-17-methyl-9a,13a,14a-morphanin, and salts, prodrugs and metabolites thereof, together with a pharmaceutically acceptable carrier, to a human being or animal in need thereof, to achieve an antitussive effect. The present invention is further drawn to a method of achieving an antitussive effect in a human being or animal which comprises transdermally administering dextromethorphan, (+)-3-methoxy-17-methyl-9a,13a,14a-morphanin, and salts, prodrugs and metabolites thereof, together with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 23, 1998
    Date of Patent: January 1, 2002
    Assignee: Pharmacia & Upjohn AB
    Inventors: Ulla Hoeck, Bo Kreilgaard, Helle Kristensen